コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 th masses similar to or greater than that of Jupiter.
2 = 57.0 days) with a mass 0.37 times that of Jupiter.
3 ing the planets and forming a retrograde hot Jupiter.
4 isotopic composition is the same as that of Jupiter.
5 dies in orbit about the Sun between Mars and Jupiter.
6 nterior of Saturn, and to a lesser extent in Jupiter.
7 he Earth's atmosphere has been discovered in Jupiter.
8 enomenon similar to that on the Earth and in Jupiter.
9 ith mass no greater than a few times that of Jupiter.
10 n contrast to a recent claim for another hot Jupiter.
11 her latitudes flow both east and west, as on Jupiter.
12 seasonal scales at mid- and low latitudes on Jupiter.
13 ers and resonances with one another and with Jupiter.
14 4.617 days and a mass at least 0.69 that of Jupiter.
15 l influence of the newly formed giant planet Jupiter.
16 ays and a minimum mass of 1.14 times that of Jupiter.
17 morphologically from those of both Earth and Jupiter.
18 m, possibly not at its present location near Jupiter.
19 es in polygonal patterns around the poles of Jupiter.
20 retrograde co-orbital asteroid of the planet Jupiter.
21 core-accretion process that may have formed Jupiter.
22 ative energy balance on other planets, as on Jupiter.
23 l energy balance in the middle atmosphere of Jupiter.
24 rmation models indicate a mass twice that of Jupiter.
25 chaos and applying it to Mercury and to hot Jupiters.
26 n migration as a mechanism for producing hot Jupiters.
27 System, and contrasts with the isolated hot Jupiters.
28 ons would be implicated as the origin of hot Jupiters.
29 monoxide (CO) have been detected in two hot Jupiters.
30 ms occur with a frequency similar to the hot Jupiters.
31 te a major channel for the production of hot Jupiters.
32 Intervention Trial Evaluating Rosuvastatin (JUPITER), 17 802 apparently healthy men and women with l
33 planet's mass is at most three times that of Jupiter; a higher mass would lead to gravitational disru
35 ontrolled trials of both primary prevention (JUPITER and ASCOT) and secondary prevention (CARE and PR
36 st to planets with masses similar to that of Jupiter and higher, the bulk compositions of planets in
37 planet candidate is roughly the same size as Jupiter and is no more than 14 times as massive (with 95
38 emissions associated with the interaction of Jupiter and its satellite Io extend to a surprisingly hi
39 rms of asteroids following the same orbit as Jupiter and located at the L4 and L5 stable Lagrange poi
40 limited by camera sensitivity, distance from Jupiter and long exposures (about 680 milliseconds to 85
41 of small objects orbiting primarily between Jupiter and Neptune--with an equivalent radius of 124 +/
42 .71 and approximately 0.27 times the mass of Jupiter and orbital separations of approximately 2.3 and
46 y when the orbital effects of large planets (Jupiter and Saturn) and damping mechanisms, such as gas
48 itu dust instruments around the icy moons of Jupiter and Saturn, but have hitherto not been observed
49 ion on other icy bodies such as the moons of Jupiter and Saturn, has remained undetected in cometary
50 h show that a popular formation scenario for Jupiter and Saturn, in which Jupiter migrates inward fro
51 al differences between the magnetospheres of Jupiter and Saturn, it has been suggested that cryovolca
52 the internal structures and compositions of Jupiter and Saturn, resulting in profound revisions of o
53 to be important for particle acceleration at Jupiter and Saturn, the electric field produced in the i
54 t step in forming gas-giant planets, such as Jupiter and Saturn, was the production of solid 'cores'
62 Intervention Trial Evaluating Rosuvastatin (JUPITER) and performed replication in a meta-analysis of
63 Intervention Trial Evaluating Rosuvastatin (JUPITER) and synthesized the results with prior trials.
64 isk, and 25 in those at high genetic risk in JUPITER, and 57, 47, and 20, respectively, in ASCOT.
65 the planetary mass at four times the mass of Jupiter, and constrains the planet's tidal luminosity.
66 rther stratify risk in patients eligible for JUPITER, and could be used to target subgroups of patien
67 red during cruise phase outside the orbit of Jupiter, and find a statistical upper limit on the optic
68 explanation for the high obliquities of hot Jupiters, and dynamical interactions would be implicated
69 gration that produces warm Jupiters over hot Jupiters, and they provide evidence for a population of
70 een in the auroral emissions from Saturn and Jupiter are due to scaling differences in the conditions
74 revealed that a considerable fraction of hot Jupiters are on orbits that are misaligned with respect
79 Among such intermediate-risk patients, a JUPITER-based strategy becomes cost-saving at a rosuvast
81 oid belt lies between the orbits of Mars and Jupiter, but the region is not uniformly filled with ast
83 e orbits lie close to their host stars ('hot Jupiters') can largely be accounted for by planetary mig
86 rticular, we predict that liquid iron in the Jupiter core is in the "rigid liquid" state and is highl
88 tween a large planetary embryo and the proto-Jupiter could have shattered its primordial compact core
89 ligned electron beams associated with the Io-Jupiter coupling, for example, create an auroral footpri
90 results from a comparative study of ten hot Jupiters covering the wavelength range 0.3-5 micrometres
94 ses, the dispersed millisecond pulses called Jupiter dispersed pulses (JDPs) provide evidence of low
96 2.6 million women age > or =60 years meeting JUPITER eligibility criteria had fasting LDL-C <130 mg/d
98 ligible participants, 18.2% (n = 1,621) were JUPITER-eligible (hs-CRP > or = 2.0 mg/l, LDL-C <130 mg/
100 this study is to describe the proportion of "JUPITER-eligible" (Justification for the Use of statins
103 with observations and in studies of the hot Jupiter exoplanet HD 189733b leads to up to a 20-fold in
106 rared observations of more than a dozen 'hot-Jupiter' extrasolar planets have now been reported.
109 in situ measurement of the D/H ratio in the Jupiter family comet 67P/Churyumov-Gerasimenko by the RO
110 the direct in situ measurement of N2 in the Jupiter family comet 67P/Churyumov-Gerasimenko, made by
111 wide range of D/H ratios in the water within Jupiter family objects and preclude the idea that this r
112 rs per second from an orbit close to that of Jupiter-family comets (Tisserand's parameter = 2.8 +/- 0
115 ly given the inputs and limits of the model; Jupiter Florida/Vero Beach, the Cape Hatteras Tropical L
116 is has been interpreted as evidence that hot-Jupiter formation is linked to dynamical disruption, as
118 ovided the motivation for our meta-analysis (JUPITER) had little impact on the findings for venous th
119 has only one large satellite, Titan, whereas Jupiter has four large satellites; additional large sate
122 ng outer ice shell about the tidal axis with Jupiter, has been proposed as a possible explanation for
124 ement between the mass retrieved for the hot Jupiter HD 189733b from transmission spectroscopy with t
125 Intervention Trial Evaluating Rosuvastatin (JUPITER), HDL size and HDL-P were measured by nuclear ma
128 l friction, and find that we can produce hot Jupiters in orbits that are retrograde with respect to t
129 tion in the deep metallic hydrogen region of Jupiter is believed to generate its magnetic field, the
130 actions with the solar wind, whereas that at Jupiter is formed through interactions with plasma from
133 cipants in the randomized placebo-controlled JUPITER (Justification for the Use of Statins in Prevent
134 vastatin in apparently healthy adults in the JUPITER (Justification for the Use of Statins in Prevent
135 luate the cost-effectiveness of applying the JUPITER (Justification for the Use of statins in Prevent
137 or patients with a proinflammatory response, JUPITER (Justification for the Use of Statins in Prevent
139 rdiac Outcomes Trial-Lipid-Lowering Arm] and JUPITER [Justification for the Use of Statins in Prevent
140 ency (=0.02), and randomized clinical trial (JUPITER [Justification for the Use of Statins in Primary
141 count for the mass loss required to reduce a Jupiter-like gas giant, they can remove a small (a few E
143 guration of these planets, combined with the Jupiter-like size of their host star-named TRAPPIST-1-ma
144 ightness of the host star, combined with its Jupiter-like size, offers the possibility of thoroughly
145 gnetosphere was reduced, resulting in a more Jupiter-like system, in agreement with the dearth of aur
146 95 per cent upper limit on the frequency of Jupiter-mass free-floating or wide-orbit planets of 0.25
147 a large population of unbound or wide-orbit Jupiter-mass planets (reported to be almost twice as com
149 rbital period of 0.94 days and a mass of ten Jupiter masses (10 M(Jup)), resulting in a tidal interac
151 131399Ab is one of the lowest mass (4 +/- 1 Jupiter masses) and coldest (850 +/- 50 kelvin) exoplane
155 on scenario for Jupiter and Saturn, in which Jupiter migrates inward from a > 5 astronomical units (A
156 artery disease (CAD) in both the WGHS and in JUPITER (N = 8,749), a randomized trial of rosuvastatin
157 tiple mechanisms for generating lightning on Jupiter need to be considered for a full understanding o
158 his efficient separation is the formation of Jupiter, opening a gap in the disk and preventing the ex
159 extrasolar giant planets--the so-called 'hot Jupiters'--orbit within 0.05 au of their primary stars (
160 ere I report the detection of an unusual hot Jupiter orbiting the primary star of a triple stellar sy
162 ersion of tidal migration that produces warm Jupiters over hot Jupiters, and they provide evidence fo
166 ith those with eGFR >or=60 ml/min/1.73 m(2), JUPITER participants with moderate CKD had higher vascul
168 Intervention Trial Evaluating Rosuvastatin (JUPITER) participants, we tested whether lipids, apolipo
169 spacecraft acquired science observations of Jupiter, passing less than 5000 kilometers above the equ
170 h for planetary companions orbiting near hot Jupiter planet candidates (Jupiter-size candidates with
172 in space exploration missions (i.e., Venus &Jupiter planetary exploration, and heliophysics missions
173 o be abundant in the upper atmosphere of hot-Jupiter planets, but is not identifiable here; therefore
178 ng has been seen on other planets, including Jupiter, polar lightning has been known only on Earth.
180 association between these quartiles and the JUPITER primary endpoint of first non-fatal myocardial i
182 meta-analysis across the WOSCOPS, ASCOT, and JUPITER primary prevention, relative risk reduction in t
183 w exoplanets with sizes between 0.37 and 1.6 Jupiter radii and orbital periods from 3.2 to 4.9 days w
185 of 0.07 astronomical units, a radius of 0.4 Jupiter radii, and a mass of less than 0.18 Jupiter mass
186 of the hot Jupiter, the innermost planet was Jupiter (rather than Mercury) sized, and its chaotic evo
187 intervention Trial Evaluating Rosuvastatin (JUPITER) reignited attention on the link between statin
188 d spectral measurements over five successive Jupiter rotations at spatial resolutions of 200 to 140 k
189 nvection originating near the 5-bar level of Jupiter's atmosphere (assuming photon scattering from po
194 However, preliminary in situ measurements of Jupiter's auroral regions yielded no evidence of such a
199 ximately 2 x 10(-8) is comparable to that of Jupiter's faintest gossamer ring, although its particle
201 1) has provided an accurate determination of Jupiter's gravitational field(2), which has been used to
204 he comparatively sparse crater population on Jupiter's icy moon Europa and suggest that this assumpti
207 plasmoids-and contains ions from both Io and Jupiter's ionosphere with intense bursts of H(+) and H(+
210 Intense electromagnetic impulses induced by Jupiter's lightning have been recognised to produce both
212 and the barely understood electron beams in Jupiter's magnetosphere, demonstrate that anti-planetwar
213 conclusively demonstrated by observations in Jupiter's magnetosphere, which--like that of Saturn (but
221 on several moons of the outer planets, with Jupiter's moon Europa having received the most attention
222 We report far-ultraviolet observations of Jupiter's moon Europa taken by Space Telescope Imaging S
223 perature or extreme radiation (e.g. Mercury, Jupiter's moon Europa, near-Sun comets), as well as terr
226 te observations of other icy bodies, such as Jupiter's moons Europa and Ganymede, and suggestive of a
229 that inner Oort Cloud objects can penetrate Jupiter's orbit via a largely unexplored dynamical pathw
235 s that the passage of ring particles through Jupiter's shadow creates the Thebe extension and fully a
236 spacecraft's encounter with Amalthea, one of Jupiter's small inner moons, on 5 November 2002 yield a
238 esults indicate that the interaction between Jupiter's upper atmosphere and near-space environment is
242 ave acceleration could also be important for Jupiter, Saturn and other astrophysical objects with mag
243 ults presented have potential application to Jupiter, Saturn and other magnetized astrophysical objec
244 erall properties of the satellite systems of Jupiter, Saturn and Uranus arise naturally, and suggest
245 ous ultraviolet imaging we find that, unlike Jupiter, Saturn's aurorae respond strongly to solar wind
246 han being intermediate between the Earth and Jupiter, Saturn's auroral emissions behave fundamentally
248 masses almost equal to 5 to 20 times that of Jupiter, showing they bridge the gap between hotter brow
249 orbiting near hot Jupiter planet candidates (Jupiter-size candidates with orbital periods near 3 d) i
250 st decade, observations of giant exoplanets (Jupiter-size) have provided key insights into their atmo
251 detected atomic and molecular absorption in Jupiter-sized exoplanets, but intense efforts to measure
253 , similar to the CVD event rate noted in the JUPITER study placebo group (1.36% per year over 1.9 yea
255 the L4 and L5 stable Lagrange points of the Jupiter-Sun system (leading and following Jupiter by 60
258 ation in this system (and possibly other hot-Jupiter systems) must be much weaker than in the Solar S
260 y flux from discrete acceleration is less at Jupiter than that caused by broadband or stochastic proc
261 Our results reveal a diverse group of hot Jupiters that exhibit a continuum from clear to cloudy a
263 of rosuvastatin were 50% of that observed in JUPITER, the incremental cost-effectiveness ratio would
270 Intervention Trial Evaluating Rosuvastatin (JUPITER), to a target population of trial-eligible patie
271 objects that are more than 10x as massive as Jupiter, to intermediate-mass Neptune-like objects with
272 y healthy men and women participating in the JUPITER trial (87% of full cohort), we prospectively ass
274 months in a nested case-control study of the JUPITER trial (Justification for the Use of Statins in P
275 ssed in 9612 multiethnic participants in the JUPITER trial (Justification for the Use of Statins in P
276 of treatment effectiveness were based on the JUPITER trial and were varied in sensitivity analyses.
281 dertook an analysis of participants from the JUPITER trial to address the balance of vascular benefit
282 cipants in the randomised placebo-controlled JUPITER trial were adults without diabetes or previous c
287 Intervention Trial Evaluating Rosuvastatin (JUPITER) trial before randomization to rosuvastatin 20 m
288 Intervention Trial Evaluating Rosuvastatin (JUPITER) trial of 17,802 initially healthy men and women
289 Intervention Trial Evaluating Rosuvastatin (JUPITER) trial of rosuvastatin users identified a sub-ge
293 -wavelength photometry of the transiting hot-Jupiter WASP-12b that reveals C/O >/= 1 in its atmospher
295 rted into a true mass of 1.85(-0.42)(+0.52)M(Jupiter), which implies that it is a planet, not a brown
296 anomalously large radius (1.35 times that of Jupiter), which may be the result of ongoing tidal dissi
298 resent evidence that observed eccentric warm Jupiters with eccentric giant companions have mutual inc
299 In contrast, comparison studies of warm Jupiters (with slightly larger orbits) and hot Neptune-s
300 Absolute CVD rates (per 100 person-years) in JUPITER women for rosuvastatin and placebo (0.57 and 1.0